ImmunityBio Stock Falls Despite Promising Bladder Cancer Treatment Results
ImmunityBio's ANKTIVA shows strong efficacy in bladder cancer trials, yet the company's stock drops 7.25%.
ImmunityBio's ANKTIVA shows strong efficacy in bladder cancer trials, yet the company's stock drops 7.25%. This is an original Token Times brief based on reporting by Blockonomi, with live market data added, as of Fri, 16 Oct 2026 18:00:01 UTC.
ANKTIVA's impressive results could transform bladder cancer treatment, but investor sentiment remains cautious despite the breakthrough.
- ANKTIVA delivers a 71% complete response rate in bladder cancer trials.
- Median response duration is 26.6 months, with some exceeding 53 months.
- Three-year data shows 84% of responders remain cystectomy-free.
- FDA expands ANKTIVA's use based on trial outcomes.
ImmunityBio's stock dropped by 7.25% to $9.27 despite promising results from its ANKTIVA trial for bladder cancer treatment. The trial demonstrated a 71% complete response rate among 100 patients, indicating strong potential for the treatment.
The median duration of response for patients was 26.6 months, with some responses lasting beyond 53 months. Additionally, three-year data showed that 84% of responding patients remained cystectomy-free, highlighting the long-term efficacy of ANKTIVA.
Both Blockonomi and The Cryptonomist report these findings, with Blockonomi focusing on the clinical outcomes and The Cryptonomist analyzing the market reaction. Despite the positive trial results, investor sentiment appears mixed, as evidenced by the stock's decline.
The FDA has expanded ANKTIVA's use based on the trial data, further underscoring its potential as a treatment option. This regulatory decision adds credibility to the treatment's effectiveness and could pave the way for wider adoption.
In the broader market context, the total crypto market cap stands at $2.8 trillion, with 
Bitcoin down 0.87% in the last 24 hours. The overall market remains relatively flat, with a Fear & Greed index of 63, indicating a sentiment of 'Greed.'
ImmunityBio Stock Falls Despite Promising Bladder Cancer Tre — questions & answers
What were the key results of the ANKTIVA trial?
The trial showed a 71% complete response rate, a median response duration of 26.6 months, and 84% cystectomy-free survival at three years.
Why did ImmunityBio's stock drop despite positive trial results?
Investor sentiment may be influenced by broader market conditions or concerns about the treatment's commercial potential.
What is the significance of the FDA's decision?
The FDA's expansion of ANKTIVA's use validates its efficacy and could lead to broader adoption in bladder cancer treatment.
Which outlets reported this story?
This is an original Token Times brief that synthesises reporting from Blockonomi. It is not a copy of any one article — follow the source links above for the original reporting.
Original summary — not financial advice. This is an original Token Times brief that summarises a development reported elsewhere and adds live market data for context; it is not the original article and reproduces no part of it. Follow the source link above for full details. Crypto is volatile and high-risk — always do your own research.